NZ597940A - Method for making 3alpha-hydroxy, 3beta- methyl-5alpha-pregnan-20-one (ganaxolone) - Google Patents
Method for making 3alpha-hydroxy, 3beta- methyl-5alpha-pregnan-20-one (ganaxolone)Info
- Publication number
- NZ597940A NZ597940A NZ597940A NZ59794010A NZ597940A NZ 597940 A NZ597940 A NZ 597940A NZ 597940 A NZ597940 A NZ 597940A NZ 59794010 A NZ59794010 A NZ 59794010A NZ 597940 A NZ597940 A NZ 597940A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- methylating agent
- halide
- ganaxolone
- iron
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23355309P | 2009-08-13 | 2009-08-13 | |
| PCT/US2010/045176 WO2011019821A2 (en) | 2009-08-13 | 2010-08-11 | METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597940A true NZ597940A (en) | 2013-03-28 |
Family
ID=43586809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597940A NZ597940A (en) | 2009-08-13 | 2010-08-11 | Method for making 3alpha-hydroxy, 3beta- methyl-5alpha-pregnan-20-one (ganaxolone) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8362286B2 (https=) |
| EP (1) | EP2464653B1 (https=) |
| JP (1) | JP5745517B2 (https=) |
| KR (1) | KR101778603B1 (https=) |
| CN (1) | CN102549007B (https=) |
| AU (1) | AU2010282570B2 (https=) |
| BR (1) | BR112012003085B1 (https=) |
| CA (1) | CA2769820C (https=) |
| EA (1) | EA024269B1 (https=) |
| ES (1) | ES2524724T3 (https=) |
| IL (1) | IL217857A (https=) |
| MX (1) | MX2012001728A (https=) |
| NZ (1) | NZ597940A (https=) |
| WO (1) | WO2011019821A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| US9629853B2 (en) | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| CZ305837B6 (cs) * | 2015-02-25 | 2016-03-30 | Vysoká škola chemicko - technologická v Praze | (3α,5β,20S)-3-Nitrooxy-pregnan-20-karboxylová kyselina |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| CN106366149B (zh) * | 2016-08-09 | 2018-01-23 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮分散片的有关物质及其分析检测方法 |
| CN106279326A (zh) * | 2016-08-09 | 2017-01-04 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮胶囊的有关物质及其分析检测方法 |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| IT201800009683A1 (it) * | 2018-10-22 | 2020-04-22 | Ind Chimica Srl | Processo per la preparazione di 3α-idrossi-5α-pregnan-20-one (brexanolone) |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CN114728012A (zh) | 2019-08-05 | 2022-07-08 | 马瑞纳斯制药公司 | 用于治疗癫痫持续状态的加奈索酮 |
| JP7780431B2 (ja) | 2019-12-06 | 2025-12-04 | マリナス ファーマシューティカルズ， インコーポレイテッド | 結節性硬化症の治療での使用のためのガナキソロン |
| IT202000021316A1 (it) * | 2020-09-09 | 2022-03-09 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| FR2720747B1 (fr) * | 1994-06-02 | 1996-07-12 | Roussel Uclaf | Nouveau procédé de préparation d'un stéroïde 16béta-méthyl et nouveaux intermédiaires. |
| FI972202L (fi) * | 1994-11-23 | 1997-07-17 | Cocensys Inc | Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun |
| US20060009432A1 (en) * | 2004-07-09 | 2006-01-12 | Roger Whiting | Use of neurosteroids to treat neuropathic pain |
| CN101583620B (zh) * | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
-
2010
- 2010-08-11 AU AU2010282570A patent/AU2010282570B2/en active Active
- 2010-08-11 EP EP10808696.8A patent/EP2464653B1/en active Active
- 2010-08-11 CN CN201080035660.3A patent/CN102549007B/zh active Active
- 2010-08-11 CA CA2769820A patent/CA2769820C/en active Active
- 2010-08-11 EA EA201270241A patent/EA024269B1/ru active IP Right Revival
- 2010-08-11 KR KR1020127006429A patent/KR101778603B1/ko active Active
- 2010-08-11 WO PCT/US2010/045176 patent/WO2011019821A2/en not_active Ceased
- 2010-08-11 NZ NZ597940A patent/NZ597940A/xx unknown
- 2010-08-11 MX MX2012001728A patent/MX2012001728A/es active IP Right Grant
- 2010-08-11 JP JP2012524841A patent/JP5745517B2/ja active Active
- 2010-08-11 BR BR112012003085-0A patent/BR112012003085B1/pt active IP Right Grant
- 2010-08-11 US US12/854,226 patent/US8362286B2/en active Active
- 2010-08-11 ES ES10808696.8T patent/ES2524724T3/es active Active
-
2012
- 2012-01-31 IL IL217857A patent/IL217857A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010282570B2 (en) | 2014-04-24 |
| KR101778603B1 (ko) | 2017-09-14 |
| EA024269B1 (ru) | 2016-09-30 |
| EP2464653A4 (en) | 2013-01-16 |
| JP5745517B2 (ja) | 2015-07-08 |
| EA201270241A1 (ru) | 2013-09-30 |
| CA2769820C (en) | 2017-06-27 |
| ES2524724T3 (es) | 2014-12-11 |
| AU2010282570A1 (en) | 2012-02-23 |
| HK1171761A1 (en) | 2013-04-05 |
| CA2769820A1 (en) | 2011-02-17 |
| IL217857A0 (en) | 2012-03-29 |
| IL217857A (en) | 2016-03-31 |
| JP2013501803A (ja) | 2013-01-17 |
| WO2011019821A3 (en) | 2011-06-16 |
| BR112012003085A2 (pt) | 2020-12-01 |
| CN102549007A (zh) | 2012-07-04 |
| EP2464653A2 (en) | 2012-06-20 |
| BR112012003085B1 (pt) | 2021-06-01 |
| US8362286B2 (en) | 2013-01-29 |
| KR20120084715A (ko) | 2012-07-30 |
| US20110040112A1 (en) | 2011-02-17 |
| CN102549007B (zh) | 2015-03-18 |
| WO2011019821A2 (en) | 2011-02-17 |
| MX2012001728A (es) | 2012-06-01 |
| EP2464653B1 (en) | 2014-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597940A (en) | Method for making 3alpha-hydroxy, 3beta- methyl-5alpha-pregnan-20-one (ganaxolone) | |
| PH12018500562A1 (en) | Methods of synthesizing a prostacyclin analog | |
| JP2013501803A5 (https=) | ||
| MX2009013827A (es) | Compuestos antivirales. | |
| EA201891841A1 (ru) | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов | |
| EP4406594A3 (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| PT2182800E (pt) | N-cicloalquil-benzil-tiocarboxamidas, ou derivados ncicloalquil- benzil-n?-substitu?dos-amidina fungicidas | |
| JP2009526034A5 (https=) | ||
| DE602004024880D1 (de) | Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten | |
| NZ593712A (en) | Intermediates for synthesising nucleoside aryl phosphoramidates | |
| WO2007131072A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
| BR112013024223A2 (pt) | composto de poliéter, agente de cura usando o composto de poliéter, e método de produção do composto de poliéter | |
| MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
| MY183861A (en) | Pyrazolopyrimidine derivative | |
| DE602007002915D1 (de) | 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| RU2012150501A (ru) | Противораковые стероидные лактоны, ненасыщенные в положении 7(8) | |
| MX2014008247A (es) | Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento. | |
| MY155959A (en) | Use of indole derivatives as nurr-1 activators for treating parkinson's disease. | |
| TW200633989A (en) | Method for producing (4,5-dihydroisoxazolo-3-yl)thioformamidine chloride | |
| MX2015012346A (es) | Derivados de pirazolilbenzo[d]imidazol. | |
| GB201303161D0 (en) | Methods and compositions for treating cancer metastasis | |
| SG11201809988WA (en) | Composition for browning inhibition and use of same | |
| NZ590076A (en) | Treating plexiform neurofibroma and related tumors | |
| Chicha et al. | N-(1-Allyl-1H-indazol-5-yl)-4-methylbenzenesulfonamide | |
| Chicha et al. | N-(3-Chloro-1-methyl-1H-indazol-5-yl)-4-methylbenzenesulfonamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2017 BY CPA GLOBAL Effective date: 20140626 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2018 BY CPA GLOBAL Effective date: 20170629 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2019 BY CPA GLOBAL Effective date: 20181004 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2020 BY CPA GLOBAL Effective date: 20190628 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2021 BY CPA GLOBAL Effective date: 20200625 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2022 BY THOMSON REUTERS Effective date: 20210702 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2023 BY THOMSON REUTERS Effective date: 20220704 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2024 BY THOMSON REUTERS Effective date: 20230703 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2025 BY THOMSON REUTERS Effective date: 20240702 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 AUG 2026 BY THOMSON REUTERS Effective date: 20250701 |